Evaluating Cytisine for Smoking Cessation
Analysis and Evaluation of Smoking Treatment With Cytisine: Retrospective Observational Study
This study tests if Cytisine can help people with moderate to severe tobacco addiction quit smoking successfully.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 65 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Regina Elena Cancer Institute Academic / other |
| Locations | 1 site (Rome) |
| Trial ID | NCT06439303 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the effectiveness of Cytisine, a medication prescribed for smoking cessation, in patients with moderate to severe tobacco use disorder. It involves a retrospective analysis of patients who underwent an initial examination at the Anti-Smoking Center of the National Institute Regina Elena. The study will evaluate treatment adherence, efficacy, and tolerability of Cytisine as a monotherapy for smoking cessation during a specified period. Data will be collected from patients who attended follow-up visits after receiving the treatment.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old suffering from moderate or severe tobacco use disorder who are prescribed Cytisine.
Not a fit: Patients with contraindications to Cytisine or those undergoing treatment for neoplastic conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a cost-effective therapeutic alternative for individuals struggling with tobacco addiction.
How similar studies have performed: While there is limited research on Cytisine specifically, other studies on smoking cessation treatments have shown varying degrees of success, indicating potential for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients aged \> 18 years; * patients suffering from moderate or severe tobacco use disorder; * prescription of pharmacological therapy with Cytisine; * patients returned to the 1st check-up on schedule; Exclusion Criteria: * Patients with contraindications to taking Cytisine and partial receptor agonists nicotinic cholinergics; * Patients undergoing pharmacological or physical treatment for neoplastic pathology; * Pregnant or breastfeeding women; * Patients for whom specific information for objective assessments is not available;
Where this trial is running
Rome
- "Regina Elena" National Cancer Institute — Rome, Italy (Recruiting)
Study contacts
- Study coordinator: Maria Papale, Doctor
- Email: maria.papale@ifo.it
- Phone: 0652666903
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.